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Rheumatoid cachexia: the underappreciated 
role of myoblast, macrophage and fibroblast 
interplay in the skeletal muscle niche
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Abstract 
Although rheumatoid arthritis affects 1% of the global population, the role of rheumatoid cachexia, which occurs 
in up to a third of patients, is relatively neglected as research focus, despite its significant contribution to decreased 
quality of life in patients. A better understanding of the cellular and molecular processes involved in rheumatoid 
cachexia, as well as its potential treatment, is dependent on elucidation of the intricate interactions of the cells 
involved, such as myoblasts, fibroblasts and macrophages. Persistent RA-associated inflammation results in a relative 
depletion of the capacity for regeneration and repair in the satellite cell niche. The repair that does proceed is subop-
timal due to dysregulated communication from the other cellular role players in this multi-cellular environment. This 
includes the incomplete switch in macrophage phenotype resulting in a lingering pro-inflammatory state within the 
tissues, as well as fibroblast-associated dysregulation of the dynamic control of the extracellular matrix. Additional to 
this endogenous dysregulation, some treatment strategies for RA may exacerbate muscle wasting and no multi-cell 
investigation has been done in this context. This review summarizes the most recent literature characterising clinical 
RA cachexia and links these features to the roles of and complex communication between multiple cellular contribu-
tors in the muscle niche, highlighting the importance of a targeted approach to therapeutic intervention.
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Introduction
Rheumatoid arthritis (RA) is a multifactorial disease 
that affects approximately 1% of the global population. 
Whilst the exact aetiology of RA is still being elucidated, 
it is known that both genetic and environmental fac-
tors initiate the auto-immune response against the syn-
ovium by stimulating several cell types and their cytokine 
secretome [1, 2].
RA targets not only the joints, but also the surrounding 
tissues and their resident and infiltrating cellular compo-
nents resulting in disability and impaired quality of life 
[3, 4]. In this context, a recent review [5] highlighted the 
underappreciated status of skeletal muscle and empha-
sized the significant role of muscle health in the pre-
venting disability and cardiometabolic disease. In RA 
patients there is a reported 7.4–14.0% decrease in muscle 
mass compared to matched controls, which frequently 
occurs with a concomitant increase in fat mass [3]. A 
recent meta-analysis indicated the presence of rheu-
matoid cachexia in 15–32% of RA cases [6]. Cachexia is 
defined as a “complex metabolic syndrome associated 
with underlying illness and characterized by loss of mus-
cle with or without loss of fat mass” [7]. Cachexia can be 
diagnosed through the assessment of body composition 
with either bioimpedance analysis or dual energy X-ray 
absorptiometry (DEXA) [8]. It may be beneficial to con-
sider additional factors for diagnosis including: anorexia, 
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inflammation, metabolic disturbances, physical output, 
and quality of life [9].The exact molecular mechanisms 
involved in rheumatoid cachexia are still unclear, but 
the most popular hypotheses include reduced physi-
cal activity associated with joint pain, pro-inflammatory 
cytokine-induced catabolism, insulin resistance, insuf-
ficient protein ingestion and reduced anabolism [4, 10]. 
It is also possible that these different mechanisms occur 
concomitantly or separately during the different phases 
of disease. These hypotheses are, in part, based on the 
links between inflammation, muscle loss and dysfunc-
tion that have been elucidated in other diseases as diverse 
as diabetes and cancer [11–14]. Although rheumatoid 
cachexia may share some of the mechanisms, the nature 
of auto-immune diseases increases the complexity of 
the inflammatory milieu. Another factor to consider is 
that which neuroinflammation associated with RA pre-
sents prior to joint destruction, and the potential effect 
this may have muscle innervation and the loss of mass 
and strength, although not sufficiently investigated [15, 
16]. The early onset of inflammation opens the window 
for earlier treatment targeted at specific mechanisms of 
rheumatoid cachexia. Earlier intervention could feasi-
bly delay the point where dysregulation is so severe that 
cachexia becomes clinically evident. It is therefore imper-
ative to determine the causative mechanisms involved in 
rheumatoid cachexia, to provide the basis for the devel-
opment of early diagnostic predictors, as well as new 
preventative and therapeutic strategies targeting the reg-
ulatory mechanisms.
A limitation of studies investigating the dysregulation 
of different cellular role players in rheumatoid cachexia, 
is that they neglect the complex interaction by focussing 
on one particular cell type in isolation. Although useful in 
terms of assessing cellular dysfunction, this does not pro-
vide a complete picture of rheumatoid cachexia aetiology. 
Skeletal muscle is a complex tissue niche, containing sev-
eral co-existing resident cell types, including myoblasts, 
fibroblasts and a variety of immune cells, which affect 
each other multi-directionally via various molecular 
communication mechanisms.
Due to alterations in the relative distribution and type 
of immune and cells fibroblasts in different myopathies 
[17], a comprehensive, integrative assessment of their 
availability and intercellular signalling in RA is vital to 
form a holistic picture of dysregulation and/or muscle 
pathology. As RA is an auto-immune disease, its inflam-
matory profile is somewhat unique when compared to 
other chronic inflammatory diseases [18], so that mere 
suppression of inflammation—either in circulation or 
in the synovia—may not be sufficient to prevent RA-
associated detrimental effects on skeletal muscle health. 
Additionally, inflammation contributes to muscle repair 
processes and pure suppression would therefore impair 
regeneration [19], as discussed in later sections. Thus, a 
more comprehensive, integrated understanding of the 
different role players involved in rheumatoid cachexia is 
required to further develop treatment strategies.
This review will provide a brief overview of the known 
dysregulation and clinical manifestation of rheumatoid 
cachexia, as well as potential aetiological role players. It 
is followed by a discussion focussed on integrating the 
roles of the different cell types present in the muscle 
niche and their paracrine communication in the con-
text of RA-associated inflammation and muscle de- and 
regeneration.
The clinical features of rheumatoid cachexia within skeletal 
muscle
The centrally reported feature of rheumatoid cachexia 
is the presence of increased levels of pro-inflamma-
tory cytokines (systemic and locally), tumour necrosis 
factor-α (TNF-α) and interleukin-1β (IL-1β) [6]—which 
are also primarily targeted in current treatment modali-
ties. In skeletal muscle, inflammation affects normal 
protein turnover as well as its response to injury. Both 
processes involve coordinated remodelling of skeletal 
muscle tissue with the latter involving the activation, pro-
liferation and differentiation of satellite cells—muscle-
specific stem cells [20].
Skeletal muscle mass is easily influenced both posi-
tively and negatively, either through hypertrophy or 
atrophy, both of which are facilitated by signalling path-
ways involved in protein turnover [21]. Hypertrophy 
of the muscle occurs in response to growth stimuli and 
an increase in protein synthesis, while muscle atro-
phy occurs with several pathological states including 
chronic inflammation, disuse and ageing. Cachexia is a 
well-known consequence of a number of chronic inflam-
matory diseases including cancer, chronic obstruc-
tive pulmonary disease (COPD), chronic heart disease 
(CHD), cystic fibrosis and RA, amongst others [22]. 
However, the functional effects of the associated muscle 
atrophy are underestimated, especially since rheumatoid 
cachexia exhibits both reduced muscle mass and muscle 
performance, which may lead to disability, poor quality of 
life and increased mortality.
The specific aetiological role players that determine 
rheumatoid cachexia outcome are summarised next.
Clinical disease severity correlates with loss of skeletal 
muscle fibre size
Cross-sectional area (CSA) is indicative of the potential 
for muscle force output which is affected not only by 
muscle size, but also density, fascicle length and the angle 
of pennation. Several studies in RA patients and animal 
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models of RA report that RA is characterised by a par-
allel loss of CSA and strength. An early study reported 
a simple linear regression between grip strength and 
muscle CSA for both healthy and RA individuals [23]. In 
line with this, a rodent collagen-induced arthritis (CIA) 
model indicated a strong correlation between clini-
cal disease scores (arthritis severity in peripheral joints) 
and locomotion, which was associated with a significant 
loss in muscle mass across multiple muscle types (tibialis 
anterior (TA), extensor digitorum longus (EDL), soleus 
and gastrocnemius muscles) [24]. Similarly, another 
rodent study using the same CIA model demonstrated 
reduced myofibre CSA of gastrocnemius and TA mus-
cles alongside severe arthritic changes including exten-
sive bone erosion and cartilage thinning, within 45 days 
of onset. In this study, a significant inverse correlation 
was reported between disease clinical scores and myofi-
bre CSA, highlighting the relationship between disease 
severity and degree of atrophy [4]. Based on these stud-
ies, it is clear that a reduction in CSA occurs as a result 
of RA and is one of the key identifying factors of rheuma-
toid cachexia.
Cachexia profile is time‑dependent and not dependent 
on pain‑associated inactivity
Initially, it was suggested that the atrophy associated 
with RA occurred as a result of inactivity due to painful 
joints. However, it has since been observed that muscle 
atrophy and weakness are already present before pain 
and swelling affect the physical activity of the RA patient 
[25]. For example, a reduction in several performance 
outcomes such as knee extension, grip and trunk exten-
sion strengths, as well as overall muscle strength index 
(29%), were reported in RA patients when compared to 
controls, at a time point early after clinical onset of RA, 
and preceding bone mineral density loss [26]. Patients 
with stable RA and uncompromised appendicular lean 
mass exhibited significantly higher body fat percentage 
and significantly smaller vastus lateralis muscle CSA 
than matched controls, as well as a reduction in objective 
physical function [27]. This suggests that CSA is already 
affected from early stage disease and is not rescued even 
when patients reach a stable state. However, in another 
report, a reduction in CSA did not affect contractile 
properties, activation capacity and concentric force, or 
power elicited by electrical stimulation—a finding that 
may indicate some loss in voluntary activation due to 
pain. Alternatively, since pennation angle was reduced 
with atrophy, this might explain an improved direction 
of force transduction with maximal stimulation despite 
reduced CSA [27]. Taken together, these data support 
the conclusion that skeletal muscle CSA is altered early 
in disease progression and contributes to loss of function 
in RA patients. This suggests that at least some compen-
satory muscle regenerative mechanisms may be activated 
with time, to counter early cachexia-associated loss of 
strength. These events at cellular levels remain to be fully 
elucidated as will be discussed later in this review.
Body composition contributes to the severity 
of cachexia‑induced muscle function deficit
Another potential determining factor in the reduction 
of muscle strength is the accumulation of intramuscular 
fat (as indicated by decreased muscle density on quan-
titative computer tomography (QCT) scans). Low mus-
cle density is indicative of increased myocellular lipid 
content and fatty infiltration in the interstitial space and 
is a strong negative indicator of muscle quality. In this 
context, a cross-sectional study on 60 RA patients indi-
cated associations between a low skeletal muscle fat mass 
(within individual muscles; includes fat inside myocytes 
and around the muscle fibres) and more effective perfor-
mance, including greater speed and quadriceps muscle 
strength [28]. Similarly, excessive total body fat (obesity) 
seems to also be a contributing factor in the decline of 
muscle function. Kramer et  al. (2012) demonstrated an 
inverse relationship between muscle density and body 
fat mass in the context of RA. The same study reported 
a correlation between muscle density decline and numer-
ous factors related to the inflammatory profile such as 
increased age, RA duration, IL-6 and TNF-α levels, as 
well as circulating endogenous glucocorticoids [29]. 
Taken together, these data illustrate the important role 
of inflammatory activation in determining muscle func-
tion and highlight that the combination of metabolic and 
inflammatory dysregulation adds to the complexity of the 
disease in RA patients.
The role of skeletal muscle fibre type composition
In terms of muscle type-specific sensitivity to rheuma-
toid cachexia, reports are varied. Generally, changes in 
catabolic responses between predominantly glycolytic 
or oxidative skeletal muscle types have been assessed in 
several non-RA models of chronic inflammation includ-
ing burn-injury [30], chronic heart failure [31], and sep-
sis [32] with data suggesting that fast-twitch glycolytic 
muscles are more prone to atrophy. In RA specifically, 
early patient-based studies have reported the most severe 
atrophy in type II fibres from the quadriceps femoris 
muscle [33, 34]. Of interest to the current review topic, 
some also reported increased collagen fibril deposition 
around fibres exhibiting mild necrosis (but not in fibres 
with severe atrophy or necrosis) [34]. This is in line with 
our earlier suggestion that cachectic muscle may activate 
regenerative counter-mechanisms.
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Recent animal studies utilizing the CIA model are 
however more contradictory. On one hand, assessing 
the gastrocnemius as a predominantly fast-twitch and 
the soleus as a predominantly slow-twitch muscle, the 
loss of muscle mass in rats was more pronounced in the 
gastrocnemius than the soleus [35]. Similarly, in female 
cynomolgus monkeys, irregularity in muscle fibre size 
and more prominent atrophy in type II muscle fibres 
5  weeks after initial immunization was demonstrated 
[36]. In contrast, no difference in muscle weight and force 
production deficits between soleus and EDL muscles 
were reported in mice, suggesting that changes in gas-
trocnemius and EDL muscles might differ [37]. However, 
a recent study done by our group assessing the gastroc-
nemius, soleus and EDL muscles in rats, demonstrated 
a severe (≈60%) loss of muscle mass, but with similar 
severity in terms of reduction in CSA, left shift of fibre 
size distribution and histological evidence of fibre degra-
dation [38], supporting the argument against muscle fibre 
type as major role player. Interestingly, atrophy was less 
pronounced in the vastus lateralis muscle, which suggests 
that other factors, such as body posture, distance of mus-
cle from affected joints, or even muscle-specific differ-
ences in redox profile—which was detailed in this study 
[34]—may contribute relatively more to final outcome 
than fibre type itself.
The next sections will provide a more in-depth expla-
nation of the complex signalling from multiple cellular 
role players contributing to rheumatoid cachexia.
Proinflammatory cytokine‑induced protein degradation 
and catabolism in rheumatoid cachexia
Skeletal muscle is a relatively adaptive tissue and is 
composed of muscle fibres connected within the extra-
cellular matrix (ECM). Skeletal muscle cells are par-
ticularly protein rich and the normally encountered 
mechanical strains require a basal protein turnover to 
enable maintenance of structural and functional pro-
teins, adjustments to important regulatory functions 
and a plethora of adaptive responses. It is important 
that this process of protein turnover remains balanced, 
as a small increase in degradation or a decrease in 
synthesis can result in a reduction in overall cell mass 
which ultimately leads to muscle atrophy [10]. As 
depicted in Fig.  1, systemic inflammation promotes 
protein degradation which leads to the loss of body cell 
mass, and unfortunately targets predominantly lean 
muscle tissue [19, 39–43].
Taken together, these studies again indicate that the 
increase in protein catabolism is largely associated with 
an increased presence of pro-inflammatory cytokines, 
which ultimately results in rheumatoid cachexia. The 
fact that elevated cytokine expression no doubt occurs 
prior to clinical manifestation of RA joint symptoms, 
also explains why the loss of muscle mass is already 
observed in patients early after clinical onset of RA.
Fig. 1 Pathways of proinflammatory cytokine-induced protein degradation in rheumatoid cachexia. (ref [35, 40–45]). TNFα tumor necrosis factor-α, 
NFκB  nuclear factor kappa-light chain enhancer of activated B cells, IL-1β  interleukin-1β, PPARγ  peroxisome proliferator activated receptor-gamma
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Cellular mediators and molecular dysregulation giving rise 
to rheumatoid cachexia
Characterisation of muscle pathology in rheumatoid 
cachexia has gradually progressed since microscopic 
assessments of different muscle groups in 100 RA 
patients first revealed muscle fibre atrophy, abundant 
fibrinoid material and immune cells over 40  years ago 
[44]. A decade after this first report, the muscle pathol-
ogy associated with RA was determined to be more com-
plex and was labelled rheumatoid myositis (RM). This 
was based on electron microscopy evidence of necrosis, 
varied degrees of atrophy, infiltration of mononuclear 
cells and myopathic changes. Other reported features 
included fewer and widely separated myofibrils, the 
presence of more collagen fibrils (on the myofibre sur-
face and in extracellular spaces) as well as disorientated 
myofilaments [34]. These early papers already high-
lighted the involvement of multiple different cell types 
in RA pathology. More recent studies further indicate 
that it is possible for patients with RA to show signs of 
muscle regeneration. For example, Boutrup and col-
leagues recently demonstrated that higher myonuclear 
content in muscle fibres in vastus lateralis muscle biop-
sies taken from RA patients, when compared to healthy 
controls [45]. This suggests that donation of additional 
nuclei from the satellite cell pool occurred as a possible 
compensatory mechanism to preserve muscle health/
function.
Below, we review the most relevant literature on rel-
evant cellular role players and their molecular interac-
tions. For clarity of the argument, interactions between 
skeletal muscle and inflammatory cells are discussed first, 
in terms of the balance between tissue de- and regenera-
tion. This is followed by a literature overview and discus-
sion of the interplay of fibroblasts and fibrosis in terms of 
quality of muscle repair.
Satellite cell activation and cell–cell cross‑talk in response 
to inflammation and during regeneration and regrowth
Skeletal muscle has a unique ability to regenerate 
throughout life due to the presence of satellite cells. 
Satellite cells reside between the basal lamina and the 
sarcolemma and in close proximity to capillaries [46], 
thus poised to be influenced by the mature muscle cells 
(fibres), ECM, other cells in the niche and circulating fac-
tors. Under healthy, resting conditions, the satellite cells 
remain quiescent. However, these cells play a major role 
following injury, at which time they are rapidly activated 
to proliferate, differentiate and fuse in order to repair the 
damaged area [47]. Mechanical loading of muscle with 
chronic underlying pathology leads to acute damage [48]. 
Hence, skeletal muscle may be required to go through 
episodic regeneration. Over the past decade, another 
resident interstitial mesenchymal-like stem cell, the fibro-
adipogenic progenitor (FAP) cell, has been identified as 
important in regulating satellite cells [49] via engaging in 
communication with other cells in the satellite cell niche 
[50]. These include immune cells and fibroblasts which 
play critical roles in all the stages of muscle repair [51]. 
Figure  2 summarises the relationship between the dif-
ferent cell type influencing muscle growth and repair in 
inflammatory conditions such as rheumatoid arthritis 
[34, 49–65].
In a chronic inflammatory setting such as RA, the 
persistent imbalance of pro- and anti-inflammatory 
macrophages disturbs normal muscle regeneration by 
impairing satellite cell proliferation and differentiation 
[51, 55, 56]. It is important that the macrophage subtypes 
work together to maintain the balance between prolifer-
ating and differentiating satellite cells. In a rodent model 
of RA, an imbalance between M1 and M2 macrophages 
favouring excess M1, has been shown to be related to 
continued invasion of monocytes into synovial tissue 
[66]. Similarly, macrophage inflitration perpetuates dam-
age in chronic muscle pathologies [67]. It is conceiv-
able that this occurs in the muscle of RA patients, even 
though the muscle damage is a secondary pathology. 
Given this evidence of the involvement of macrophages 
and/or their secreted cytokines as critical contributors to 
the maintenance of skeletal muscle integrity, a dysregu-
latory shift in macrophage phenotype can significantly 
alter the delicate balance between proliferation, differen-
tiation, and fusion of myoblasts to repair or maintain the 
muscle fibres. In order to better understand the feasibil-
ity of therapeutically targeting macrophages in RA, it is 
necessary to better understand the different immune cell 
types involved.
A more in‑depth review of dysregulated macrophage 
polarization in RA
In joints with RA, the synovial membrane is also com-
plex in terms of cellular profile, containing activated 
B- and T-cells, plasma cells, mast cells, and monocytes. 
Additionally, the presence of activated synovial fibro-
blasts, chondrocytes, and osteoclasts contributes to car-
tilage and bone destruction and continued inflammation 
through the sustained release of cytokines [68]. These 
cell types are not limited to the synovial joint and can be 
found across numerous tissue types, including skeletal 
muscle [55]. Maladaptation, disease-associated pathol-
ogy or therapeutic interference with the inflammatory 
response can affect the possibility of synovial joint and 
muscle repair and long-term function significantly. When 
targeting macrophages for therapeutic effect, the phe-
notype plasticity of macrophages complicates matters. 
Temporary ablation of macrophages/monocytes through 
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diphtheria toxin injection after cardiotoxin injury in the 
TA muscle of mice was reported to attenuate the phe-
notypic switch of macrophage subsets and ultimately 
impair muscle regeneration [69]. Conversely, co-injection 
of pro-inflammatory macrophages with myoblasts into 
regenerating mouse skeletal muscle resulted in the gen-
eration of twice as many fibres after 4  weeks compared 
to myoblasts alone or myoblasts with anti-inflammatory 
macrophages in vivo. In this study, subsequent co-culture 
of myoblasts and macrophages illustrated that co-culture 
with pro-inflammatory M1 macrophages resulted in an 
increase in the number of proliferating myoblasts and a 
decrease in differentiation. The opposite was observed 
with anti-inflammatory M2 macrophage co-culture [19]. 
This indicates that while persistent inflammation can be 
detrimental to muscle, and despite the opposing roles 
of M1 and M2 macrophages, the synchronised presence 
of both phenotypes is vital for optimal skeletal muscle 
regeneration.
Pro-inflammatory M1 macrophages arise in 
response to IFN-γ, TNF-α, granulocyte–macrophage 
colony-stimulating factor (GM-CSF) and lipopolysaccha-
ride (LPS)/endotoxin in the early stages of muscle repair. 
Their major role is the removal of necrotic material and to 
process and present antigens to activate T-cells. M1 mac-
rophages produce pro-inflammatory cytokines TNF-α 
and IL-1β. The M2 macrophage population is more com-
plex and can be divided into four subtypes, namely M2a, 
b, c, and d. M2a macrophages are activated by IL-4 and 
IL-13 and contribute to tissue repair, wound healing and 
fibrosis in most scenarios of muscle damage. M2a mac-
rophages are most abundant in the later stages of mus-
cle repair [54, 57] and contribute to fibrosis through the 
secretion of transforming growth factor (TGF)-β, insu-
lin-like growth factor (IGF) and fibronectin.
In acute damage scenarios, M2a macrophages will 
switch to M2c macrophages once the inflammatory 
stimulus is abolished, due to a change in the intracellular 
cytokine profile. Specifically, M2c macrophages are acti-
vated by IL-10 and TGF-β and release anti-inflammatory 
cytokines, in particular IL-10, to resolve inflammation 
and limit fibrosis [70]. However, in scenarios of prolonged 
Fig. 2 The imbalance between pro- and anti-inflammatory signalling in RA rodent skeletal muscle, and the resulting influence on muscle repair 
and growth. FAP  fibro-adipogenic progenitor cell
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or chronic inflammation, M2b macrophages are predom-
inantly found. Various signalling factors are involved in 
the polarisation of macrophages towards a predominance 
of M2b macrophages, including NF-κB, mitogen-acti-
vated protein kinases (MAPKs), PI3K/Akt and interferon 
regulatory factors (IRFs). M2b macrophages display the 
capacity to secrete both pro-inflammatory cytokines 
such as TNF-α, IL-1β and IL-6, and anti-inflammatory 
cytokines such as IL-10 [71, 72], but the factors deter-
mining the nett profile of their secretomes are less clear. 
M2b macrophages are thought to have a role in limiting 
fibrosis after acute cardiac muscle injury [72]. Recently, 
micro-RNA (miRNA)-125a-5p overexpression [73] and 
chemokine (C–C motif ) ligand 1 (CCL1) signalling [74] 
was however implicated in the M2b polarisation seen in 
juvenile idiopathic arthritis which is associated with poor 
resolution of inflammation.
Studies suggest that RA patients exhibit persis-
tence of more pro-inflammatory macrophage phe-
notypes when compared to patients with peripheral 
spondylarthritis [75] and osteoarthritis [76], where 
a shift towards an M2 phenotype has been reported. 
Macrophage depletion using clodronate-containing 
liposomes prior to initiation of arthritis in a CIA rodent 
model resulted in reduced M1 cell presence in the 
joint, alongside a reduction in arthritis disease score, 
indicating the importance of M1 macrophages in the 
development of RA [77]. However, further investiga-
tion is required to fully understand the significance of 
the M2 subset shifts in RA aetiology. Nonetheless, it 
would seem that in chronic inflammatory disease, the 
natural phenotype shift—which occurs via cytokine-
induced polarisation—is skewed to limit the complete 
phenotype transition to achieve anti-inflammatory M2c 
macrophages  (Fig.  3). The extracellular signalling fac-
tors responsible for this phenomenon, are ideal candi-
dates for therapeutic targeting. (The M2d phenotype is 
associated with angiogenesis in tumour growth and not 
relevant to the current topic.) 
Fig. 3 Representative images suggesting the presence of different cell types in healthy versus rheumatoid arthritis skeletal muscle. Fluorescent 
images from a RA rodent model (study execution described in Oyenihi et al., 2019 [38]; staining method described in Additional file 1) indicate 
clear cachexia and increased fibrosis between muscle fibres. Black and white images indicative of the authors prediction of greater presence of 
macrophages (M1 and M2b) and fibroblasts in RA
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Fibroblasts and the extracellular matrix (ECM)
During the regeneration and remodelling phases after 
muscle injury, structural aspects of muscle are in flux and 
hence muscle quality may be reduced. Fibroblasts secrete 
several growth factors and ECM components (fibronec-
tin, collagen I and III, and proteoglycans) during main-
tenance and repair. Following damage, binding of ECM 
components (such as fibrin and fibronectin) to the colla-
gens and proteoglycans form a temporary matrix within 
the injury site. This provides a suitable environment for 
differentiating myoblasts and a scaffold for regenerating 
myofibres [78–80].
Myofibroblasts contribute to tissue repair through 
wound contracture but may also play a role in the forma-
tion of fibrosis. Myofibroblasts were originally thought to 
be derived only from differentiating resident fibroblasts, 
however, they can also arise from parenchymal epithelial 
cells through epithelial to mesenchymal transition (EMT) 
[81, 82] and from FAPs [83]. For optimal repair, these 
cells are present in damaged muscle only transiently, 
with a rapid reduction in their numbers in the regenerat-
ing area. However, in chronic situations, the persistence 
of FAPs and their differentiation into myofibroblasts 
and adipocytes results in intramuscular fibrofatty infil-
tration [50, 83]. Here, macrophage dysregulation comes 
into play: the increase in TGF-β secretion by M2 mac-
rophages blocks the TNF-α-induced apoptosis, result-
ing in prolonged FAP survival. Although not directly 
assessed in RA, the increased muscle fat mass reported 
in RA suggest that these processes also contribute to RA 
myopathy.
Degradation of the temporary ECM occurs after suf-
ficient repair to allow for the optimal growth of the 
regenerating fibres [65, 81]. Matrix metalloproteinases 
(MMPs) produced by damaged myofibres and infiltrat-
ing cells play a key role in the degradation of this tem-
porary ECM [50, 84]. However, the excessive deposition 
of ECM and impaired degradation via TGF-β-dependent 
mechanisms leads to interstitial fibrosis and subsequent 
loss of tissue architecture and function. Within the skel-
etal muscle, excessive ECM deposition, especially colla-
gens, results in impaired muscle fibre regeneration and 
increased susceptibility to re-injury, ultimately causing 
morbidity and mortality [81, 82].
Macrophages are attracted to the damaged tissue by 
chemoattractant cytokines and secrete cytokines that 
indirectly stimulate the production of ECM components, 
as summarized in Fig. 4. M1 macrophages release TNF-α 
and IL-6 which stimulate the proliferation of fibroblasts 
and FAPs [85], but upon binding to excess fibrinogen 
also increase the production of IL-1β and TGF-β [86]. 
TNF-α and IL-1β increase the synthesis of collagenases 
contributing to the destruction of the cartilage in RA 
[45, 53, 56]. M2a macrophages play a profound role in 
fibrosis due to the fact that they release a large range of 
pro-inflammatory molecules such as TGF-β, fibronec-
tin, several TIMPs and CCL17 [56, 82]. In addition, both 
CCL3 (macrophage inflammatory protein 1α) and CCL2 
(monocyte chemoattractant protein-1) have been high-
lighted as promotors of fibrosis through their chemotac-
tic properties [81]. To add to this, fibroblasts were shown 
to have the capacity to promote arthritis through the 
production of GM-CSF, which enhances the survival of 
neutrophils and macrophages [87], thus further strength-
ening the inflammatory response in a vicious cycle, much 
like the self-propagating oxidative damage-inflammation 
cycle that also comes into play in chronic diseases such 
as RA [38]. Disturbance in the balance between classi-
cally activated (M1) and alternative (M2) macrophages 
therefore leads to excessive TGF-β production, resulting 
in excessive activation of fibroblasts and inhibited apop-
tosis of FAPs, resulting in excessive ECM production 
and fibrosis [56, 80]. Related to this, it was suggested by 
Khoja [28] that the accumulation of fat around the mus-
cle spindles may lead to a similar effect with thicken-
ing of the capsule and fibrotic changes in the intrafusal 
muscle fibres. This has not yet been sufficiently assessed 
in the context of RA, warranting further research in this 
context.
One of the most important factors involved in tissue 
healing and fibrosis is TGFβ. This profibrotic growth fac-
tor is present in skeletal muscle following injury and in 
dystrophic muscle, where it stimulates fibroblasts to pro-
duce ECM components [79, 88]. During regeneration, the 
degradation of the initial scaffold of ECM contributes to 
the generation of protein fragments that mediate biologi-
cal activities involved in normal tissue repair [73, 79, 85]. 
However, TGFβ reduces the production of enzymes (such 
as collagenase) and stimulates the production of tissue 
inhibitors of metalloproteinases (TIMPs) and plasmino-
gen activator inhibitor type-1 (PAI-1), thereby inhibiting 
the degradation of the ECM [83, 88] and disturbing the 
final outcome.
Gene expression analysis of skeletal muscle samples 
from RA patients demonstrated a correlation between 
disease activity and disability and increased concentra-
tions of amino acid precursors to muscle fibrosis [20]. 
Analysis of blood samples from patients with active 
RA highlighted differences in cell–cell interactions, 
altered EMT, and increased TGF-β proteins sugges-
tive of increased de novo ECM synthesis and fibrosis 
[89]. Fibrosis has been demonstrated in several tissues 
from RA patients and rodent studies. For example, 
increased fibrous tissue deposition was demonstrated 
in the joint of RA rodents 6  days post induction with 
fluorescent visualization of collagen III and fibrinogen 
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[90]. Similarly, research from our group has demon-
strated a significant increase in collagen accumulation 
within the vastus lateralis, soleus and gastrocnemius 
muscles in CIA rodents compared to that of control 
rodents [38], as well as impaired molecular remodelling 
with fibrotic deposition and impaired cardiomyofibre 
contractile function [91]. In humans, the presence of 
subclinical myocardial fibrosis resulting from low grade 
chronic inflammation in a large number of RA patients, 
has been linked to heart failure in approximately 3.9% 
of patients [92]. Furthermore, pulmonary fibrosis is 
often associated with RA as a result of increased TGF-β 
and Smad signalling leading to an increase in collagen 
deposition within the lung tissue [93]. The assessment 
of fibrosis in RA skeletal muscle tissue is limited, how-
ever in chronic inflammation, macrophages expressing 
both pro- and anti-inflammatory cytokines (TNFα and 
TGFβ) were reported to have a reduced ability to clear 
FAPs from the damaged tissue [50]. Cross-talk between 
these cells and satellite cells also occurs via TGFβ. 
In  vitro, it has been demonstrated that the isoform of 
TGFβ has an influence on the satellite cell response 
[94]. Therefore, a full understanding of the role of TGFβ 
in RA may require that level of sophistication, which 
can be achieved in vitro in single cell culture or co-cul-
ture. In chronic kidney disease, chronic inflammation 
resulted in increased muscle collagen content which 
also correlated with increased abundance of FAPs [95].
To further complicate matters, in  vitro studies have 
demonstrated that satellite cells themselves also secrete 
factors that regulate ECM gene expression independent 
of TGF-β [96, 97]. The use of Pax7 knock-out mice indi-
cated that satellite cells are critical to limit ECM deposi-
tion and prevent fibrosis in the first week of regeneration, 
potentially through a mechanism involving microRNA 
and exosomes circulating the skeletal muscle. For exam-
ple, microRNA-206 (miR-206) is highly expressed in 
satellite cells and satellite cell-derived exosomes; it per-
forms its actions through binding to and inhibiting ribo-
somal binding protein 1 (Rrbp1), a master regulator of 
collagen synthesis. Knockdown of miR-206 resulted in 
the increased expression of collagen genes in fibrogenic 
cells [97], proposing a potential mechanism of fibrogenic 
pathogenesis in chronic inflammatory disorders such as 
RA. The potential for therapeutic or preventative inter-
vention at this level warrants further investigation.
Fig. 4 Summary of the interaction between macrophages, fibroblasts and FAPs in the development of tissue fibrosis. TNF-α  tumor necrosis 
factor-alpha, IL-6  interleukin-6, TGFβ  transforming growth factor-beta, FAPs  fibro-adipogenic progenitor cells, TIMPs  tissue inhibitor of 
metalloproteinase, MMPs  metalloproteinases
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Finding therapeutic targets in the context of RA
From the literature presented above, it is clear that 
complex, aberrant intracellular communication result-
ing from auto-immune activation—and thus persistent 
inflammation—results in the complex syndrome of rheu-
matoid cachexia.
We present a predictive image of the muscle niche in 
Fig.  3  and a visual summary of the literature in Fig.  5. 
In our opinion, the main site of dysregulation in RA, is 
the incomplete phenotype switch from M1 to M2c mac-
rophages, which is reflected by an “indecisive” M2b phe-
notype which can signal either pro- or anti-inflammatory, 
depending on signalling from its extracellular environ-
ment, but does either ineffectively. This has several 
knock-on effects, such as the dysregulation of the ECM, 
which limits satellite cell activation and function, as well 
as contributing to fibrosis. Both these outcomes then fur-
ther affect other cell types in a self-reinforcing chronic 
cascade resulting in the increased fat and collagen depo-
sition, and loss of muscle fibre maintenance observed in 
rheumatoid cachexia.
In our opinion, there are two main avenues to follow 
for therapeutic intervention. Firstly, an obvious therapeu-
tic strategy would be to prevent the incomplete M1-M2 
transition of macrophages. Secondly, modulation of the 
RA ECM would not only correct satellite cell functional-
ity, but also improve mature muscle fibre and whole mus-
cle functionality and force output, both of which would 
significantly contribute to complete repair and return to 
function. A specific target for this approach would be 
to reduce the proliferation of fibroblasts, present in the 
affected muscle as well as the affected joint. However, 
fibroblasts do not act alone in the development of fibro-
sis, which is also stimulated by FAPs and macrophages. 
Of course, given the complexity of the disease and inter-
play of contributing cell types—especially once properly 
established—it would be naïve to consider intervention at 
any one site in isolation.
The fact that rheumatoid cachexia occurs secondary 
to primary auto-immune disease, and that inflammation 
itself is a systemic phenomenon rather than a local one, 
adds complexity to the quest for a therapeutic strategy. 
However, recent advances in drug delivery systems and 
nanotechnology may hold promise for delivery of mod-
ulating factors into the muscle ECM. Due to the greater 
presence of macrophages in affected tissues, the pro-
posed use of drugs encapsulated by phagosome-arrested 
macrophages to deliver treatment to the desired site is a 
promising one [98]. Additionally, the use of macrophages 
to deliver satellite cells to the affected muscle holds 
promise in promoting skeletal muscle regeneration [99].
Are current treatment strategies failing?
Perhaps due to the complexity of RA as a condition (and 
even the lack of clarity regarding its precise aetiologi-
cal trigger), as well as the limitations to be overcome in 
the development of targeted therapeutic approaches, 
therapeutic strategies for RA still have ample room for 
improvement. The main therapeutic goal of current treat-
ment strategies is to induce sustained clinical remission 
or to maintain a low-inflammatory activity of the disease 
if remission is not possible [100]. This section will give an 
overview of the current treatment strategies and briefly 
outline which of these strategies shows potential in terms 
of targeting the sites we have identified, in the context of 
delaying or limiting the extent of rheumatoid cachexia.
Popular treatment options for RA vary from the use of 
non-steroidal anti-inflammatory drugs (NSAIDs), glu-
cocorticoids, disease-modifying anti-rheumatic drugs 
(DMARDs), and more recently, biological-response 
mediators [101, 102]. The treat-to-target (T2T) approach 
has been found to be more effective than specific treat-
ment strategies and incorporates aspects such as tight 
control and monitoring of disease and its biological side 
effects, and therapeutic adjustments when set targets are 
not met [103]. NSAIDs and glucocorticoids are consid-
ered a first-line therapy and act to rapidly reduce pain 
and swelling in the affected joints by transiently reduc-
ing the inflammation present. The use of both NSAIDs 
and glucocorticoids are only recommended as short-term 
treatment or as bridge therapy while the DMARDs gain 
sufficient effectivity, as they neither slow the progres-
sion of RA, nor have disease modifying effects and are 
linked to a large number of adverse effects [104, 105]. 
(See figure on next page.)
Fig. 5 Summary of the cellular interactions in chronic inflammation leading to a decline in muscle growth. The incomplete switch from M1 to M2c 
results in a greater presence of M2b macrophages which present both impaired pro- and impaired anti-inflammatory properties, often resulting 
in enhanced deposition of ECM components, and impaired satellite cell function. This also results in a reduced presence of M2c macrophages. 
The mechanisms and pathways presented are based on chronic inflammatory microenvironments (proposed in RA), with blue indicating 
mechanisms confirmed in studies of RA. Different colours indicate different cell focus areas; green = muscle niche; purple = inflammatory system; 
red = fibroblasts and fibrosis. Increased signalling are indicated by double-line arrows, while dotted line arrows indicate decreased signalling. 
SCs  satellite cells, IGF  insulin-like growth factor, Murf-1  muscle ring finger protein-1, Mafbx  muscle atrophy f-box, exos  exosomes, Rrbp1  ribosome 
binding protein-1, IL  interleukin, TNF-α  tumor necrosis factor-α, IFN-γ interferon-γ, LPS  lipopolysaccharides, GM-CSF  granulocyte-monocyte 
colony-stimulating factor, TGF-β  transforming growth factor-β, TIMP  tissue inhibitor of metalloproteinase, MMP  matrix metalloproteinase, 
CTGF  connective tissue growth factor, FAPs  fibro-adipogenic progenitor cells, ECM  extracellular matrix, α-SMA  α-smooth muscle actin
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Currently, the drugs of choice for the treatment of RA are 
DMARDs [105]. DMARDs are slower acting compounds 
that improve symptoms and slow progression of RA. 
DMARDs are split into two, namely synthetic DMARDS 
and biological DMARDS [103, 105]. The most commonly 
used DMARD is methotrexate, which has several mecha-
nisms of action. It has the ability to inhibit the prolif-
eration of cells, including inflammatory-cell mediators 
and lymphocytes, as well as to reduce TNF-α and IL-1β 
expression, hence its anti-inflammatory effect [106, 107]. 
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Studies on methotrexate have also indicated a reduction 
in the accumulation of toxic compounds such as polyam-
ines that contribute to tissue damage [108] as well as a 
reduction in reactive oxygen groups in the synoviocytes 
obtained from RA patients [108]. The European League 
Against Rheumatism (EULAR) still recommends that 
immediate treatment with DMARDs should occur upon 
RA diagnosis, and despite the fact that newer thera-
peutics have been developed, methotrexate should be 
the first treatment option [103]. Whether methotrexate 
would be beneficial in rheumatoid cachexia is unknown. 
Investigation into the effects of methotrexate on satellite 
cells and skeletal muscle is lacking in the RA model and 
treatment was unable to shift macrophage phenotype to 
M2 macrophages once polarised to the M1 phenotype 
in an in  vitro model [109]. The effect of methotrexate 
on fibrosis is also less desirable—the drug were demon-
strated to be pro-fibrotic in both liver cells in vitro [110] 
and in liver tissue of RA patients [111]. While this treat-
ment may be beneficial and used as a first option therapy 
for RA, it is not necessarily beneficial in treating or pre-
venting the development of secondary symptoms such as 
rheumatoid cachexia.
In terms of biological-response modifiers, scientists 
have largely focused on suppression of systemic inflam-
mation, developing therapies targeting specific soluble or 
cell-surface molecules with the use of monoclonal anti-
bodies and receptor constructs. One of the most success-
ful targets is TNF-α inhibition (adalimumab, etanercept, 
and infliximab)—these medicines are often used in con-
junction with methotrexate [103, 112, 113]. Etanercept 
targets TNF-α type II receptor-IgG1 fusion protein while 
infliximab and adalimumab are specific TNF-α monoclo-
nal antibodies. The use of infliximab with methotrexate 
significantly improved symptoms of RA including joint 
swelling, pain, joint damage progression, and CRP con-
centration compared to that of methotrexate alone in a 
study assessing 428 patients with active RA [114]. How-
ever, in this study there was still a high rate of adverse 
events, with the most common being infections—which 
likely resulted from the blanket approach to immune 
suppression. The use of anti-TNF-α (adalimumab) treat-
ment reduced the diseased joint structural progression 
compared to methotrexate, which was further reduced 
by use of the both drugs in combination in a study on 
799 patients with active early RA (< 3  years since diag-
nosis) [115]. However, there are still patients who do not 
respond to the anti-TNF-α therapy. Additional biolog-
ics treatment approaches include the blocking of IL-6 
through anti-IL-6-receptor monoclonal antibodies [116], 
anti-B-cell therapy [117], and down-regulation of T-cell 
activation through the modulation of the co-stimula-
tory signal necessary for activation [118]. Due to many 
cytokine receptors signalling via Janus kinases (JAKs), 
another more recent treatment strategy involves JAK 
inhibitors. JAK inhibitors can be used to determine the 
effect of inhibition of several cytokines; these include 
IL-6, GM-CSF, type 1 interferons, IL-7, IL-15, and IL-21 
[119]. While still in the earlier stages of investigation, 
tofacitinib/methotrexate combination treatment has 
demonstrated suppressive effects on T-cells, B-cells and 
fibroblast-like synoviocytes, as well as reductions in 
MMPs in 15 RA patients compared methotrexate-treated 
controls [120].
Despite the advancement of therapeutic strategies to 
reduce RA disease progression and/or manage pain, not 
all of these are beneficial in the context of muscle health. 
While the cachexic effects of the drugs have not been 
sufficiently investigated in RA patients specifically, their 
commonly known pathways can be extrapolated to the 
RA context. For example, glucocorticoids decrease mus-
cle anabolism and increase muscle catabolism through 
different pathways, including the myostatin pathway, 
the IGF-1-PI3K-Akt pathway, and the NF-κB pathway 
[121]—thus, in particular patients showing significant 
RA cachexia, this treatment should be avoided or at least 
paired with therapy that may counter these undesired 
outcomes. In contrast, the use of DMARDs may also 
limit sarcopenia due to its inhibition of cytokines such as 
TNF-α and IL-6. However, DMARDS have been linked to 
increased body weight [122]—given the negative effects 
of muscle fat deposition commonly seen in rheumatoid 
cachexia, this problem may be exacerbated by these 
treatments.
Research on specific therapeutic strategies targeting 
rheumatoid cachexia are limited. Current therapeutic 
strategies to target cachexia include increasing physi-
cal activity, especially in the form of resistance exercise, 
and dietary alterations, such as a Mediterranean diet 
supplemented with omega 3 and vitamin D [123] and 
antioxidant supplements [124]. Low IGF-1 expression 
is associated with lower appendicular lean muscle index 
and muscle CSA in RA patients [125]. The use of IGF-1 
treatment increased body weight and gastrocnemius 
weight, as well as inhibiting the CIA-induced increase in 
atrogin-1 and MuRF1 expression in rodents [35]. How-
ever, IGF-1 is associated with increased cancer risk [126]. 
Treatment with a peroxisome proliferator-activated 
receptor-α (PPARα) agonist had similar effects, attenuat-
ing the decrease in gastrocnemius weight and fast-twitch 
myofibre size, and preventing the arthritis-induced 
increase in atrogin-1 and MuRF1 expression in a rodent 
CIA model [126]. In addition to positive effects in skel-
etal muscle, PPAR-α also has anti-inflammatory effects 
and studies have determined that treatment with PPAR-α 
agonist resulted in reduced oedema and arthritis score in 
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arthritic rodents [127]. However, the use of PPAR ago-
nists are not an option due to their many side effects, 
including congestive heart failure, bone fractures, liver 
disease and myopathy [128].
A number of studies have explored the idea of using 
physical activity and exercise training to improve mus-
cle strength and mobility in RA patients. Regular range 
of motion exercise over a 2  year period significantly 
improved strength, disease activity, and physical function, 
which was further improved in RA patients undergoing 
2 years of dynamic strength training [129]. A 5-week reha-
bilitation exercise program improved quadriceps strength 
and activation, and reduced subjective disability without 
exacerbating disease activity, improvements which were 
maintained at a 6 month follow up session [130]. Twelve 
weeks of moderate intensity pool exercise, comprising of 
a variety of strength, endurance and flexibility exercises, 
improved grip force and muscle function despite not 
improving aerobic capacity in RA patients [131]. During a 
6-week hand exercise programme, RA patients responded 
similarly to healthy controls, with an increase in hand 
force measurements, hand function, and increased CSA 
in the extensor digitorum communis muscle [132]. While 
the majority of these studies have demonstrated benefi-
cial effects on muscle strength and function, few of them 
report on the cachexia outcomes.
Conclusion
This review highlights the complexity and multi-direc-
tionality of cellular interplay in RA cachexia progres-
sion. More investigation is required to determine the 
specific interaction between the cell types mentioned, 
as limited research has focused on these pathways in 
terms of rheumatoid cachexia. Review of current treat-
ment strategies illustrates that blanket-approach systemic 
anti-inflammatory intervention is effective to a degree in 
RA, but not without side effects or missing the impact on 
cachexia. The severe impact of rheumatoid cachexia on 
long term patient independence highlights the impor-
tance of addressing not only the primary auto-immune 
disease, but also its secondary debilitating conditions. 
Further research is required to develop a more specifi-
cally targeted treatment approach, potentially making use 
of more specific, controlled delivery systems that may be 
incorporated into T2T approaches to limit rheumatoid 
cachexia development.
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